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Background. Recently acquired and remotely acquired latent Mycobacterium tuberculosis infection (LTBI) are clinically indis-
tinguishable, yet recent acquisition of infection is the greatest risk factor for progression to tuberculosis in immunocompetent indi-
viduals. We aimed to evaluate the ability of cellular immune signatures that differ between active tuberculosis and LTBI to distinguish 
recently from remotely acquired LTBI.
Methods. Fifty-nine individuals were recruited: 20 had active tuberculosis, 19 had recently acquired LTBI, and 20 had remotely 
acquired LTBI. The proportion of mycobacteria-specific CD4+ T cells secreting tumor necrosis factor α (TNF-α) but not interferon γ 
or interleukin 2 which had a differentiated effector phenotype (TNF-α–only TEFF), and the level of CD27 expression on IFN-γ–pro-
ducing CD4+ T cells, were detected by flow cytometry.
Results. The TNF-α–only TEFF signature was significantly higher in the group with recently acquired LTBI, compared with the 
group with remotely acquired LTBI (P < .0001), and it discriminated between these groups with high sensitivity and specificity, with 
an area under the curve of 0.87. Two signatures incorporating CD27 expression did not distinguish between recently and remotely 
acquired LTBI. Interestingly, the TNF-α–only TEFF signature in participants with recently acquired LTBI was more similar to that 
in participants with tuberculosis than that in participants with remotely acquired LTBI, suggesting that recently acquired LTBI is 
immunologically more similar to tuberculosis than remotely acquired LTBI.
Conclusions. These findings reveal marked biological heterogeneity underlying the clinically homogeneous phenotype of LTBI, 
providing a rationale for immunological risk stratification to improve targeting of LTBI treatment.
Keywords. Tuberculosis; latent M. tuberculosis infection; cellular immune signatures; risk stratification; diagnostic.
 
Identification of latent Mycobacterium tuberculosis infection 
(LTBI) and prevention of subsequent progression to tubercu-
losis is the cornerstone of tuberculosis control in most high-in-
come, low-incidence countries (such as those in Europe and 
the United States) [1–3]. However, preventive treatment is long 
(≥3  months) and can have significant side effects. It is there-
fore a clinical imperative to identify persons at greatest risk of 
progression from LTBI to tuberculosis. Among immunocom-
petent individuals (who account for the vast majority of LTBI 
and tuberculosis cases globally), the single strongest clinical risk 
factor for progression from LTBI to tuberculosis is time since 
infection [4], with the risk being much higher in the first 2 years 
after infection (1.5% annual risk) and declining dramatically 
thereafter (approximately 0.1% annual risk) [5, 6]. However, 
distinguishing recently acquired from remotely acquired LTBI 
is very challenging, time-consuming, and frequently unreliable 
in routine clinical practice.
A blood-based biomarker that could risk-stratify persons 
with LTBI by distinguishing recently acquired from remotely 
acquired infection would greatly enhance LTBI screening and 
contact investigations and reduce the number of people unnec-
essarily treated. Several studies have identified cellular immune 
subsets that differ in proportions between patients with tubercu-
losis and those with LTBI [7–10]. We previously identified differ-
ences in Mycobacterium tuberculosis–specific T-cell populations 
and cytokine secretion profiles in patients with tuberculosis 
versus those with LTBI. Specifically, we demonstrated that the 
proportion of purified protein derivative–specific CD4+ T cells 
secreting tumor necrosis factor α (TNF-α) but not interferon γ 
(IFN-γ) or interleukin 2 (IL-2) which had a differentiated effec-
tor memory (CD45RA−CCR7−CD127−) phenotype (TNF-α–
only TEFF) was able to distinguish tuberculosis from LTBI [8]. 
Others have also demonstrated that measuring the levels of 
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CD27 expression on M. tuberculosis–specific cytokine-produc-
ing CD4+ T cells has the potential to distinguish between tuber-
culosis and LTBI [9–11]. For example, the TAM-TB assay, which 
evaluates the ratio of the median fluorescence intensity of CD27 
within the whole CD4+ T-cell population to that of CD27 in the 
M. tuberculosis–specific IFN-γ+ CD4+ T cells has been shown to 
distinguish between tuberculosis in LTBI in children and adults 
[10]. Although it is increasingly believed that LTBI may be bio-
logically heterogeneous, such assays and cellular immune pro-
filing in general have not hitherto been used to dissect different 
epidemiological subgroups of LTBI that differ with respect to 
their risk of progression to tuberculosis.
We hypothesized that the long-term immune control that 
maintains host-pathogen equilibrium in remotely acquired 
established LTBI is not yet manifest in recently acquired LTBI 
where bacillary replication may initially be relatively uncon-
trolled, thereby resulting in a more differentiated effector T-cell 
phenotype. We therefore interrogated cellular immune signa-
tures in clinically and epidemiologically precisely phenotyped 
subjects with LTBI who had clear and substantial differences in 
reported times since acquisition of M. tuberculosis infection.
METHODS
Study Participants and Recruitment
Participants were prospectively enrolled between February 2009 
and May 2016 during routine National Health Service screen-
ing for tuberculosis or LTBI at one of the following National 
Health Service trusts in the United Kingdom: Imperial College 
Healthcare, Frimley Health, Bart’s Healthcare, and London 
Northwest. Participants were recruited under National Research 
Ethics Service approval (07/H0712/85 and 11/H0722/8), provided 
informed consent, and were aged ≥18  years. Individuals with 
known human immunodeficiency virus (HIV) infection were 
excluded; we did not routinely test all individuals in this cohort 
for HIV infection, but when testing had been previously clinically 
indicated, we were able to confirm that the test was negative.
Grouping Criteria
Tuberculosis was confirmed by M.  tuberculosis–positive cul-
ture of a sputum specimen (for pulmonary tuberculosis) or 
biopsy sample (for extrapulmonary tuberculosis). LTBI was 
confirmed by detection of M.  tuberculosis infection (based on 
a positive result of an IFN-γ–release assay [ie, TSPOT.TB and/
or QuantiFERON-Gold] and/or a tuberculin skin test), as well 
as the absence of symptoms of tuberculosis or clinical signs of 
tuberculosis on chest radiography. A positive tuberculin skin test 
result was defined as an induration diameter of ≥5 mm for BCG-
unvaccinated individuals and ≥15 mm for BCG-vaccinated indi-
viduals [3]. Detailed demographic and epidemiological data were 
collected for each participant by a tuberculosis nurse dedicated to 
the project, using a standardized case report form to estimate the 
likely time since M. tuberculosis exposure and infection.
Individuals with LTBI were grouped according to whether 
they had recently or remotely acquired LTBI (Supplementary 
Table 1). Individuals with LTBI who did not meet the stringent 
criteria for either group (eg, those for whom there was poten-
tial exposure between 6 months and 2 years before recruitment) 
were excluded from the study.
Recently Acquired LTBI
Individuals were considered to have recently acquired LTBI 
if they had come in to close contact with a confirmed case of 
tuberculosis within 6  months prior to recruitment and were 
identified through contact investigations according to United 
Kingdom national guidelines [3]. For this group, the time 
since the most recent exposure was established through a 
detailed questionnaire and was used as the estimated time since 
infection.
Remotely Acquired LTBI
Individuals were considered to have remotely acquired LTBI if 
they were born in a tuberculosis-endemic country or an era of 
high tuberculosis incidence (>40 cases/100 000), had lived in a 
country of low incidence for >2 years before recruitment, and 
had had no known contact with a tuberculosis case since emi-
grating or since the time at which the country of birth was no 
longer considered to have a high tuberculosis prevalence. For 
those who had emigrated from regions of high tuberculosis 
incidence but had had no known tuberculosis contact since 
emigration, the time since entry to a country with a low inci-
dence of tuberculosis was used as a proxy for the time since 
exposure and infection; this represents the minimum possible 
time since infection with M. tuberculosis.
Laboratory Measurement of Immunological Signatures
Peripheral blood mononuclear cell samples from individuals 
were processed, stored, stimulated, and analyzed for 3 pub-
lished M. tuberculosis–specific cellular immune signatures 
as described previously [8–10], with minor modifications 
(Supplementary Materials). Laboratory researchers conduct-
ing the experiments were blind to the patient groups, and each 
experiment was designed to include individuals from differing 
patient groups to avoid batch effects.
Statistical Analysis
Statistical analyses of immunological data from clinical groups 
were conducted using GraphPad Prism (version 6) and R statis-
tical programming language (version 3.1.3) [12]. Further details 
are available in the Supplementary Materials.
RESULTS
Cohort Characteristics
Fifty-nine participants were recruited and assigned to the 
untreated tuberculosis group (n = 20), the untreated recently 
acquired LTBI group (n  =  19), or the untreated remotely 
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acquired LTBI group (n = 20), based on strict predefined cri-
teria (see Methods and Supplementary Table 1). Patient demo-
graphic and clinical characteristics are presented in Table  1; 
there were no significant differences in age or sex proportions 
among groups.
Individuals in the recently acquired LTBI group were con-
tacts of patients with tuberculosis and were recruited as part 
of contact tracing, as per United Kingdom national guide-
lines [3]. Immune responses to M. tuberculosis in individuals 
with recently and remotely acquired LTBI were compared 
using the following 3 M.  tuberculosis–specific cellular 
immune signatures, which have previously been shown to 
differ between tuberculosis and LTBI: the TNF-α–only TEFF 
signature [8], the ratio of the median fluorescence intensity 
of CD27 expression on CD4+ T cells to that of CD27 expres-
sion on IFN-γ+ CD4+ T cells (determined by the TAM-TB 
assay [10]), and the proportion of IFN-γ+ CD4+ T cells 
with a CD45RA−CD27− or CD45RA−CD27+ phenotype [9]. 
The gating strategies used for each signature are shown in 
Supplementary Figure 1.
Table 1. Demographic Characteristics of the Study Cohort, Overall and by Clinical Group
Characteristic Total (n = 59) Tuberculosis (n = 20) Recently Acquired LTBI (n = 19) Remotely Acquired LTBI (n = 20)
Age, y, median (range) 38 (21–78) 41.8 (22–78) 37 (21–70) 34 (21–73)
Male sex 34 (57.6) 14 (70) 13 (68) 7 (35)
Region of birth
 Western Europe 22 (37.3) 4 (20) 8 (42.1) 4 (20)
 Eastern Europe 4 (6.8) 0 (0) 4 (21.1) 0 (0)
 Middle East and North Africa 2 (3.4) 1 (5) 0 (0) 1 (5)
 Sub-Saharan Africa 10 (16.9) 2 (1)0 3 (15.8) 5 (25)
 Indian subcontinent 11 (18.6) 9 (45) 2 (10.5) 6 (30)
 Central and Southeast Asia 7 (11.9) 3 (15) 1 (5.3) 3 (15)
 Latin America and Caribbean 3 (5.1) 1 (5) 1 (5.3) 1 (5)
Ethnicity
 White British 5 (8.5) 1 (5) 3 (15.8) 1 (5)
 White, other 9 (15.3) 2 (10) 5 (26.3) 2 (10)
 Middle Eastern/Arabic 2 (3.4) 1 (5) 0 (0) 1 (5)
 Pakistani 4 (6.8) 0 (0) 2 (10.5) 2 (10)
 Indian 16 (27.1) 10 (50) 2 (10.5) 4 (20)
 Chinese 1 (1.6) 0 (0) 0 (0) 1 (5)
 Bangladeshi 1 (1.6) 0 (0) 1 (5.3) 0 (0)
 Asian, other 6 (10.2) 3 (15) 1 (5.3) 2 (10)
 Black African 9 (15.3) 1 (5) 2 (10.5) 6 (30)
 Black Caribbean 4 (6.8) 2 (10) 2 (10.5) 0 (0)
 Hispanic/South American 2 (3.4) 0 (0) 1 (5.3) 1 (5)
Occupation
 Health or social care 9 (15.3) 2 (10) 1 (5.3) 6 (30)
 Non–health or non–social care 27 (45.8) 11(55) 11 (57.9) 5 (25)
 Retired 5 (8.5) 2 (10) 2 (10.5) 1 (5)
 Student 5 (8.5) 0 (0) 1 (5.3) 4 (20)
 Unemployed 11 (18.6) 4 (20) 4 (21.1) 3 (15)
 Unknown 2 (3.4) 1 (5) 0 (0) 1 (5)
TST result
 Positive 27 (45.8) 8 (40) 13 (68.4) 6 (30)
 Negative 3 (5.1) 0 (0) 1 (5.3) 2 (10)
 Not tested 29 (49.2) 12 (60) 5 (26.3) 12 (60)
IGRA result
 Positive 47 (79.7) 14 (70) 14 (73.7) 19 (95)
 Negative 4 (6.8) 1 (5) 2 (10.5)a 1 (5)a
 Not tested 8 (13.5) 5 (25) 3 (15.8)a 0 (0)
BCG receipt
 Yes 48 (81.4) 18 (90) 16 (84.2) 14 (70)
 No 9 (15.3) 0 (0) 3 (15.8) 6 (30)
 Unknown 2 (3.4) 2 (10) 0 (0) 0 (0)
Data are no. (%) of patients, unless otherwise indicated.
Abbreviations: IGRA, interferon γ–release assay; LTBI, latent Mycobacterium tuberculosis infection; TST, tuberculin skin test.
aThe patient(s) had a positive TST result.
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The TNF-α–Only TEFF Signature Can Distinguish Recently Acquired From 
Remotely Acquired LTBI
Evaluation of the TNF-α–only TEFF signature revealed significant 
differences in the proportion of these cells between all groups, 
with individuals with tuberculosis displaying the largest pro-
portions (median, 59.4%; interquartile range [IQR], 41%–73%), 
followed by those with recently acquired LTBI (median, 28.8%; 
IQR, 20%–40%) and those with remotely acquired LTBI 
(median, 10.7%; IQR, 4%–19%; Figure 1A). The range of the pro-
portions of TNF-α–only TEFF cells in the recently acquired LTBI 
group in the current study was far wider than in the remotely 
acquired LTBI group and is similar to that in the tuberculo-
sis patient group (Figure 1A). Receiver operating characteristic 
(ROC) curve analysis using the raw data gave an area under the 
curve (AUC) of 0.87, demonstrating that this signature was able 
to distinguish recently acquired from remotely acquired LTBI 
with a sensitivity of 89% (95% confidence interval [CI], 54.43%–
93.95%) and a specificity of 65% (95% CI, 56.34%–94.27%) when 
a cutoff of >14.0% was used (Figure 1B). When a nested 10-fold 
cross-validation (CV) method was applied to the data set, the area 
under the curve (AUC) for distinguishing recently acquired from 
remotely acquired LTBI was 0.84, with a CV error rate of 0.21. The 
TNF-α–only TEFF signature could almost completely distinguish 
between individuals with tuberculosis and those with remotely 
acquired LTBI, with an AUC of 0.99 revealed using either the raw 
data or after CV analysis (CV error rate, 0.7); comparison of these 
groups showed that a cutoff of >22.9% could distinguish between 
groups with a sensitivity of 100% (95% CI, 83.16%–100%) and a 
specificity of 95% (95% CI, 75.13%–99.87%; Figure 1C).
All individuals with recently acquired LTBI were recruited 
as part of contact tracing as per national guidelines; however, 
in some cases it may be that either their infection was actually 
acquired remotely or that the identified index case was not 
actually infectious (therefore, the reported time since infection 
may not be accurate). To address these issues, we performed 
sensitivity analyses where individuals for whom the identified 
recent exposure may not have been the cause of their infec-
tion were excluded (Supplementary Methods). In each of these 
more stringent analyses, the performance of the signature for 
discriminating between recently acquired LTBI and remotely 
acquired LTBI was unaffected (Figure 2).
Subsequent follow up since recruitment, using the London 
Tuberculosis Register, indicated that none of the study partic-
ipants with LTBI had developed tuberculosis after a follow-up 
period ranging from 1 month to 6.5 years (median, 22 months). 
This is unsurprising given that the majority (31 of 39 [79%]) 
commenced LTBI treatment after recruitment into the study.
Cellular Immune Signatures Incorporating CD27 Do Not Distinguish 
Between Recently Acquired and Remotely Acquired LTBI
M.  tuberculosis–specific immune signatures that incorpo-
rate CD27 have shown promise in distinguishing between 
tuberculosis and LTBI. CD27 staining was included in the 
flow cytometry assays for 17 cases of tuberculosis, 8 cases of 
recently acquired LTBI, and 8 cases of remotely acquired LTBI. 
M. tuberculosis–specific IFN-γ+ responses were analyzed for 2 
such signatures—the change in intensity of CD27 expression 
(determined by the TAM-TB assay) and the proportion of both 
Figure 1. The TNF-α–only TEFF signature, characterized by the proportion of CD4+ T cells secreting tumor necrosis factor α (TNF-α)-only which have a differentiated effector 
phenotype, in patients with tuberculosis, recently acquired latent Mycobacterium tuberculosis infection (LTBI), or remotely acquired LTBI. The proportion of purified protein 
derivative–specific TNF-α–only (not producing interferon γ or interleukin 2) producing CD4+ T cells with a differentiated effector memory (CD45RA−CCR7−CD127−) phenotype 
(TNF-α–only TEFF) was enumerated by flow cytometry for individuals with tuberculosis, recently acquired LTBI, or remotely acquired LTBI. A, Individual proportions of these 
cells in patients with tuberculosis (n = 20), recently acquired LTBI (n = 19), or remotely acquired LTBI (n = 20) is shown. **P < .01 and ***P < .001, by the Kruskal–Wallis test 
with the Dunn post hoc test for multiple comparisons. B and C, Receiver operating characteristic (ROC) curves demonstrating the ability of the TNF-α–only TEFF signature to 
distinguish recently acquired from remotely acquired LTBI (B) and tuberculosis from remotely acquired LTBI (C). For the ROC curves, heavy dashed lines show the true perfor-
mance of the TNF-α–only TEFF signature; smooth lines with confidence intervals show the performance of the signature after 10-fold cross-validation was applied. The area 
under the curve (AUC) for the actual data sets (actual AUC) and after cross-validation (CV) analysis are shown, as well as the CV error rate.
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CD45RA−CD27− and CD45RA−CD27+ phenotypes—and these 
signatures were compared between groups. These analyses iden-
tified significant differences between tuberculosis as compared 
to either recently acquired LTBI alone (in the case of TAM-TB 
assay) or both recently acquired and remotely acquired LTBI 
(when proportions of CD45RA−CD27− or CD45RA−CD27+ 
phenotypes were compared; Figure  3). However, these signa-
tures were not significantly different between recently acquired 
and remotely acquired LTBI and therefore would not be useful 
for discriminating between these groups.
DISCUSSION
We have demonstrated that the TNF-α–only TEFF cellular 
immune signature associates closely with the single strongest 
risk factor for progression of LTBI to tuberculosis in immuno-
competent adults: time since infection. Previous studies have 
identified several cellular immune signatures that differ between 
the clinically distinct states of tuberculosis and asymptomatic 
LTBI [8, 11, 13]. However, none have described distinct immu-
nological signatures within LTBI that correlate with a well-de-
fined risk factor for progression. We have found evidence that 
LTBI, while clinically homogeneous, with an absence of symp-
toms and normal chest radiographic findings, is immunolog-
ically heterogeneous, with the reported time since acquisition 
being a major contributing factor to that heterogeneity.
We previously demonstrated that the TNF-α–only TEFF sig-
nature distinguished tuberculosis from LTBI with high sensi-
tivity and specificity, with the proportion of these cells being 
Figure 2. Sensitivity analyses for recently acquired versus remotely acquired latent Mycobacterium tuberculosis infection (LTBI), using the TNF-α–only TEFF signa-
ture, characterized by the proportion of CD4+ T cells secreting tumor necrosis factor α (TNF-α) but not interferon γ or interleukin 2, which have a differentiated effector 
(CD45RA−CCR7−CD127−) phenotype. A direct comparison of the ability of the proportion of purified protein derivative–specific CD4+ T cells with a TNF-α–only TEFF signature 
to distinguish recently acquired from remotely acquired LTBI (n = 20) was performed using only the recently acquired LTBI where there was no possible remote exposure (ie, 
those who had not  lived in a country with high endemicity for TB) (n = 11; A), only recently acquired LTBI cases for which the index case was smear or culture positive for 
tuberculosis (n = 16; B), and only recently acquired LTBI cases for which the index case had pulmonary tuberculosis (n = 16; C). For each comparison, the upper panels show 
dot plots representing proportions of these cells for individuals in each group. ***P < .001 and ****P < .0001, by the Mann–Whitney U test. In the lower panels, receiver 
operating characteristic (ROC) curves of the percentage of TNF-α–only TEFF cells demonstrate the ability of the signature to distinguish recently acquired from remotely 
acquired LTBI. The heavy dashed lines represent the true performance of the TNF-α–only TEFF signature by using the cohort data sets, while the smooth lines with confidence 
intervals represent the performance of the signature after 10-fold cross-validation (CV) was applied. The area under the curve (AUC) for the actual data set is shown (actual 
AUC) in each ROC curve, as well as after CV analysis; the CV error rate is also given. Although the ethnic composition of the strict recently acquired LTBI group presented in 
panel A was changed to include a larger proportion of individuals who were white, it remained the case that within this subgroup, there was no significant differences in the 
TNF-α–only TEFF signature between ethnic groups.
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significantly higher in patients with tuberculosis than in 
patients with LTBI, including patients with HIV coinfection [8]. 
Here we show that the proportion of these cells is significantly 
higher during recently acquired LTBI as compared to remotely 
acquired LTBI. Consistent with this novel observation, the dif-
ference in the TNF-α–only TEFF signature between tuberculosis 
and LTBI reported by Pollock et al was derived from a cohort 
of subjects with LTBI who had mostly acquired their infection 
remotely [8]. We were therefore able to validate the use of this 
signature when discriminating tuberculosis from remotely 
acquired LTBI, demonstrating consistently high performance in 
2 independent studies and after a CV approach was used in the 
current data set. Thus, a combined cell surface loss of expres-
sion of CD45RA, CCR7, and CD127 on M. tuberculosis–specific 
CD4+ T cells is associated with both tuberculosis and recently 
acquired LTBI but not with remotely acquired LTBI.
Loss of CD27 expression on M. tuberculosis–specific IFN-γ+ 
CD4+ T cells has been shown to be associated with tuberculo-
sis when compared to LTBI in multiple studies. In this study, 
2 signatures incorporating such measurements did not differ 
significantly between recently acquired and remotely acquired 
LTBI in our cohort. This indicates that loss of CD27 expression 
on M. tuberculosis–specific CD4+ T cells, while associated with 
clinical disease [9–11], is not related to time since infection in 
patients with LTBI. However, we did demonstrate that both 
the TAM-TB assay and the proportions of CD45RA−CD27− or 
CD45RA−CD27+ IFN-γ+ CD4+ T cells differed between patients 
with tuberculosis and those with LTBI. We thus independently 
validated the ability of these signatures for discriminating 
tuberculosis from LTBI [9, 10], supporting their reproducibility.
Very few other studies to date have subclassified individuals 
with LTBI by using time since infection, when exploring immu-
nological signatures. One study demonstrated that an innate 
immune cell subset, myeloid-derived suppressor cells (which 
are known to suppress CD4+ T-cell function), was significantly 
increased during both tuberculosis and recently acquired LTBI, 
compared with treated tuberculosis and remotely acquired LTBI 
[14]. This is consistent with our findings that recently acquired 
LTBI appears immunologically comparable to tuberculosis.
The range in the proportions of TNF-α–only TEFF cells in 
the recently acquired LTBI group in the current study was far 
wider than range of those in the remotely acquired LTBI group, 
likely reflecting the relative heterogeneity in terms of the risk of 
progression that exists for patients with recently acquired LTBI, 
compared with the homogeneity of responses and very low risk 
of progression for patients with remotely acquired LTBI [4, 
6]. Studies involving M.  tuberculosis–infected macaques have 
demonstrated that the total pulmonary bacterial burden, as 
well as the M. tuberculosis burden within specific lesions in the 
lung, are higher in both recent infection and clinically man-
ifest active disease, compared with established (ie, remotely 
acquired) LTBI [15]. These microbiological data from the 
lungs of infected macaques support our immunological find-
ings that recently acquired LTBI is more similar than remotely 
acquired LTBI to tuberculosis. We speculate that patients in 
the LTBI group who have a higher TNF-α–only TEFF response, 
Figure 3. Comparison of signatures incorporating CD27 expression between patients with recently acquired latent Mycobacterium tuberculosis infection (LTBI) and those 
with remotely acquired LTBI. Cellular signatures that incorporate CD27 expression were compared between individuals with tuberculosis, those with recently acquired LTBI, 
and those with remotely acquired LTBI. A, The ratio of median fluorescence intensity (MFI) of CD27 in the whole CD4+ T-cell population to the MFI of CD27 of the purified 
protein derivative (PPD)–specific interferon γ–expressing (IFN-γ+) CD4+ T-cell population was calculated (by the TAM-TB assay [10]) and compared between groups among 
patients who satisfied the cutoff criteria for this assay (17 in the tuberculosis group, 8 with recently acquired LTBI, and 6 with remotely acquired LTBI). The proportions of 
purified protein derivative–specific CD4+ IFN-γ+ cells with a CD45RA−CD27− (B) or CD45RA−CD27+ (C) phenotype were calculated and compared between groups (15 in the 
tuberculosis group, 8 with recently acquired LTBI, and 8 with remotely acquired LTBI). *P < .05 and **P < .01, by the Kruskal–Wallis test with the Dunn post hoc test for 
multiple comparisons. ND, no difference.
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which overlaps most with the tuberculosis group, may be more 
likely to progress to tuberculosis. However, given that most 
of our cohort subsequently received LTBI treatment, we were 
unable to test this hypothesis in this study. Once validated in 
an independent cohort, a test measuring the TNF-α–only TEFF 
signature could be further developed as a second-line test to 
an IFN-γ–release assay, to substantially reduce the proportion 
of patients with remotely acquired LTBI who are offered treat-
ment, while still identifying all patients with recently acquired 
infection.
The potential for particular mycobacterial antigens to elicit 
differential immune responses in distinct subgroups of indi-
viduals with LTBI has previously been investigated. Although 
differential responses to putative “latency-associated” antigens 
have been identified [16–18], these have not hitherto been 
shown to correlate with progression to tuberculosis, the clini-
cal risk of progression, or any other clinical parameter. A recent 
study in individuals with long-standing LTBI identified some 
immunological differences that appeared to correlate with an 
unvalidated online risk calculator [19]. However, since the 
study population had been infected for an average of 12 years 
and there were no individuals with recently acquired LTBI [19], 
the participants were neither at risk of progression nor eligible 
for LTBI treatment according to guidelines. The study identi-
fied differences in the measured immunological parameters 
between treated and untreated LTBI, which has been shown 
previously for other immune signatures during both tuberculo-
sis [20–22] and LTBI [23].
Our study has some limitations. Although our cohort is 
defined by high-quality and detailed demographic, clinical, 
and epidemiological data, coupled with stringent criteria for 
recently acquired versus remotely acquired LTBI, one can never 
be certain precisely when a given individual acquired infection, 
and we cannot control for recall bias. We therefore chose to 
compare 2 subgroups of patients with LTBI with considerably 
different reported times since exposure to M. tuberculosis, based 
on the extensive epidemiological information we systematically 
collected for this study (not as part of routine practice), and we 
excluded those who did not meet our stringent predefined cri-
teria. Despite this, we cannot be certain that some individuals in 
the recently acquired LTBI group had not actually acquired their 
current infection remotely. To address this problem, we per-
formed an even stricter analysis, in which patients with recently 
acquired LTBI who had any risk of having been exposed at a 
different time to the identified recent exposure were excluded, 
with no impact on the performance of the signature.
All of the signatures presented here are measures of immune 
responses to purified protein derivative, a crude mixture of 
M. tuberculosis antigens that elicits strong, predominantly CD4+ 
T-cell cytokine responses. Although this confers good sensitiv-
ity for M.  tuberculosis infection in the immunological assays 
used here, the specificity is impaired because of cross-reactivity 
in BCG-vaccinated individuals. Thus, in clinical practice, these 
signatures would likely be used as a risk-stratification tool for 
subjects with positive results of the ESAT-6/CFP-10–based 
IFN-γ–release assay, which does reliably distinguish individuals 
with M. tuberculosis infection from recipients of BCG vaccine 
[24]. Hence, the antigenic cross-reactivity of purified protein 
derivative used in our immune signatures would not be a prob-
lem in clinical practice. Staining for CD27 was not included for 
all experiments performed in this study. Therefore, the sample 
size may have lacked sufficient statistical power to detect dif-
ferences in CD27 expression on M. tuberculosis–specific CD4+ 
T cells between patients with recently acquired LTBI and those 
with remotely acquired LTBI.
To validate our findings, a larger study in an independent 
population is now required before this test can be considered as 
a screening test for recently acquired LTBI. Ultimately, quan-
tification of the forward risk associated with the respective 
immune signatures will require a long-term prospective lon-
gitudinal cohort study of individuals with LTBI followed up 
to assess for progression to tuberculosis and correlation with 
baseline immune signatures. In this study, we were able to eval-
uate 3 immune signatures that assess the memory and matura-
tion phenotype of M. tuberculosis–specific T cells and that have 
previously been shown to differentiate tuberculosis and LTBI.
Our findings represent a significant advance on current tests 
of M. tuberculosis infection, which cannot differentiate recently 
acquired from remotely acquired LTBI [25]. Although the clin-
ical unmet need for a test to risk-stratify persons with LTBI and 
thereby better target preventive treatment is large and urgent 
[26], the notion that immunological markers might distinguish 
recently acquired from remotely acquired LTBI is relatively 
novel. Our findings suggest that an immune-based test could 
be used to differentiate between different types of LTBI and, if 
validated in subsequent larger longitudinal studies, could use-
fully risk-stratify persons with LTBI for targeted preventive 
treatment.
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